SNPX News and Press, Synaptogenix Inc. From 07/21/22

Synaptogenix Announces Corporate Update Conference Call PR Newswire NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegene...

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data PR Newswire Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company...

Synaptogenix to Present at the Cell Symposium PR Newswire NEW YORK , May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for...

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial PR Newswire - Top line results expected during the fourth quarter of 2022 - Data Safety Monitoring Board has confirmed no adverse safety issues N...

Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease PR Newswire Treatment with Bryostatin shown to increase blood vessel health, a key factor for prevention and disease reversal National Ins...

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit PR Newswire NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical...

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum PR Newswire NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing rege...

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) PR Newswire NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogeni...

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis Filing of protocol and Investigational New Drug Application expected in the first half of 2022; Clinical trial to follow PR Newswire NEW YORK , Feb...